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ABSTRACT
UDP-Glucuronosyltransferases (UGTs) conjugate a glucuronyl
group from glucuronic acid to a wide range of lipophilic substrates
to form a hydrophilic glucuronide conjugate. The glucuronide
generally has decreased bioactivity and increased water solubility
to facilitate excretion. Glucuronidation represents an important
detoxification pathway for both endogenous waste products and
xenobiotics, including drugs and harmful industrial chemicals. Two
clinically significant families of UGT enzymes are present in mam-
mals: UGT1s and UGT2s. Although the two families are distinct in
gene structure, studies using recombinant enzymes have shown
considerable overlap in their ability to glucuronidate many sub-
strates, often obscuring the relative importance of the two families
in the clearance of particular substrates in vivo. To address this
limitation, we have generated a mouse line, termed DUgt2, in which
the entire Ugt2 gene family, extending over 609 kilobase pairs, is
excised. This mouse line provides a means to determine the
contributions of the two UGT families in vivo. We demonstrate the
utility of these animals by defining for the first time the in vivo
contributions of the UGT1 and UGT2 families to glucuronidation of
the environmental estrogenic agent bisphenol A (BPA). The highest
activity toward this chemical is reported for human and rodent UGT2
enzymes. Surprisingly, our studies using the DUgt2 mice demon-
strate that, while both UGT1 and UGT2 isoforms can conjugate BPA,
clearance is largely dependent on UGT1s.
Introduction
UDP-Glucuronosyltransferases (UGTs) are membrane-bound phase
II enzymes that conjugate a wide array of lipophilic substrates with
a glucuronyl group from UDP-glucuronic acid (UDPGA). The highly
polar glucuronide conjugate generally decreases the bioactivity of the
substrate and increases its water solubility, facilitating excretion
through bile or urine. Glucuronidation is important in the metabolism
of endogenous wastes and a wide range of drugs, including many
chemotherapeutics, nonsteroidal anti-inflammatory drugs, and opioids,
and in protecting against harmful environmental agents such as
bisphenol A (BPA) and benzo-[a]-pyrene (Fang et al., 2002; Hanioka
et al., 2008; Kutsuno et al., 2013). Based on evolutionary divergence
and homology, mammalian UGTs have been organized into two major
families: The UGT1 and UGT2 families. The mammalian UGT1 family
currently contains only the UGT1A subfamily, while the mammalian
UGT2 family contains the UGT2A and UGT2B subfamilies (Mackenzie
et al., 2005; Rowland et al., 2013).
The mouse UGT1 family is encoded by theUgt1a gene. It consists of
nine functional isoforms, each encoded by a unique 59 exon spliced to
a shared set of downstream exons (Mackenzie et al., 2005). The first
exon specifies a UGT1A isoform and its substrate specificity, while the
downstream exons encode common domains such as a UDPGA binding
site and a transmembrane region (Owens et al., 2005). The three Ugt2a
and sevenUgt2b genes in mouse are located in a single cluster spanning
approximately 600 kilobase pairs (kbp) on chromosome 5 (Mackenzie
et al., 2005). Ugt2a1 and Ugt2a2, similar to Ugt1a, have unique first
exons and a shared set of downstream exons (Jedlitschky et al., 1999).
All other Ugt2 genes have a typical structure, with unique exons
encoding both the N-terminal substrate-binding domain and a C-terminal
UDPGA-binding domain and transmembrane sequence (Hum et al.,
1999). Similar to the UGT1 family, the C-terminal domains of the
UGT2 family are conserved, while the highly variable N-terminal
domains determine substrate specificity (Radominska-Pandya et al.,
1999). Many UGT isoforms exhibit activity toward a broad range of
substrates, and the specificities of different isoforms often overlap
(de Wildt et al., 1999).
Various approaches have been used to determine which UGTs are
involved in glucuronidation of particular compounds (Rowland et al.,
2013). Assignment using computational approaches is limited by the
lack of established structure-activity relations for most UGTs (Kaivosaari,
2010). The majority of current knowledge comes from assessment
of metabolism of substrates by microsomes reconstituted with
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recombinant enzymes. Such studies have shown that UGT2s are
involved in conjugation of a variety of endogenous metabolites, such as
retinoic acid and steroid hormones, as well as xenobiotics, such as
opioid analgesics (Hum et al., 1999; Radominska-Pandya et al., 2001;
Chouinard et al., 2007). While information from these studies can be
used to predict the relative importance of various enzymes in vivo,
extrapolation of in vitro results to in vivo systems remains an imperfect
practice (Lin and Wong, 2002; Miners et al., 2006). Such modeling has
to take into account not only the activities of the enzymes toward the
substrate under study but also the fact that there are quantitative and
qualitative differences in the expression of these enzymes in the tissues
exposed to the chemical. Ultimately, in vivo metabolism is required to
confirm the contribution of particular UGT enzymes to the metabolism
of a compound. However, due to the functional overlap of many
isoforms, it is often difficult to measure the contributions of one isoform
or even one UGT family in vivo.
These challenges have been encountered in defining the contribu-
tions of different UGTs to metabolism and clearance of environmental
pollutants such as BPA, a monomer commonly used in polycarbonate
materials with widespread human exposure. BPA’s reported toxicity in
mice at low doses (Richter et al., 2007), possibly through interference in
both genomic and nongenomic estrogen responses (Luconi et al., 2002),
has made it the subject of intense research (Krishnan et al., 1993). The
ability of BPA to impact physiologic processes is likely limited by the
rapid clearance of the inactive bisphenol A glucuronide (BPAG)
(Matthews et al., 2001; Völkel et al., 2002), and studies with recombinant
enzymes indicate that human UGT2B15 and rodent UGT2B1 likely
play the primary role in clearance (Yokota et al., 1999; Hanioka et al.,
2008). This has raised concerns regarding exposure of neonates to BPA
(Ginsberg and Rice, 2009), since expression of UGT2 genes during the
neonatal period is much lower than in children and adults (Coughtrie
et al., 1988; de Wildt et al., 1999; Divakaran et al., 2014). Despite
extensive efforts toward understanding the health impact of BPA
exposure, remarkably little is known regarding its metabolic pathways
in human or in the model organisms used in assessing its adverse
effects.
To address these limitations, we have generated a mouse line
homozygous for a targeted deletion of the entire Ugt2 family. We
show that loss of these enzymes does not adversely affect the
development of these animals, and that microsomes from mice lacking
allUgt2 genes can be used to establish the role of the UGT2 enzymes in
glucuronidation of xenobiotics. Most importantly, this mouse line can
be used to investigate the contribution of UGT2 enzymes to the
metabolism of drugs and xenobiotics in vivo.
Materials and Methods
Reagents and Materials. Alamethicin and (S)-naproxen were purchased
from Cayman Chemical (Ann Arbor, MI). BPA, BPAG, UDPGA, and
b-glucuronidase were purchased from Sigma-Aldrich (St. Louis, MO). Naproxen
glucuronide (napG) [(S)-naproxen acyl b-D glucuronide] was purchased from
Toronto Research Chemicals (Toronto). All solvents and other reagents were of
analytical grade or better. Zorbax Eclipse XDB-C18 and Tosoh TSKGel 80TM
columns were purchased fromAgilent Technologies (Santa Clara, CA) and Tosoh
Bioscience (Tokyo), respectively. Primer sequences can be found in Supplemental
Material.
Generation of Mouse Lines. A replacement-type targeting vector was
assembled from 129 bacterial artificial chromosomes bMQ357m23 and
bMQ37h06. DNA corresponding to the Ugt2 gene cluster was replaced with
a neomycin-resistance gene driven by the phosphoglycerate kinase promoter.
Homologous recombination of the targeting vector with the endogenous Ugt2
locus creates a 609 kbp deletion extending from 580 base pairs downstream from
the Ugt2b34 gene to 7.2 kbp upstream of the Ugt2a1/2 gene. 129S6-derived
embryonic stem (ES) cells were cultured using standard methods, and DNA was
introduced by electroporation. Cells were selected in Geneticin and were
evaluated by polymerase chain reaction (PCR) and Southern blot analysis.
Correctly targeted ES cells were introduced into C56BL/6 blastocysts and the
blastocysts introduced into B6D2F1/J foster mothers to complete their develop-
ment. All mice were maintained in specific pathogen–free housing in ventilated
caging. 129S6 mice purchased from Taconic (Hudson, NY) were bred to
chimeras to maintain the deleted locus on this genetic background. All mice used
in these studies are therefore 129S6, coisogenic for the deletedUgt2 locus. For all
studies of reproductive function, wild-type (WT) and null mice were generated
by the intercross of heterozygous animals. Serum testosterone levels were
measured by enzyme-linked immunosorbent assay (Endocrine Technologies,
Newark, CA). For some experiments mutant mice were age and sex matched at
weaning and housed together until used in an experiment. All studies were
conducted in accordance with the National institutes of Health Guide for the
Care and Use of Laboratory Animals (National Research Council, 2011) as well
as the Institutional Animal Care and Use Committee guidelines for the
University of North Carolina at Chapel Hill.
Gene Expression Assays. Total RNA was isolated from tissue homogenates
using a Quick-RNA Miniprep Kit (Zymo Research, Irvine, CA), and reverse
transcription PCR was performed using a High Capacity cDNA Reverse
Transcription Kit (Life Technologies, Grand Island, NY). cDNA was amplified
with the FastStart Universal Probe Master with Rox normalization (Roche
Applied Science, Indiana, IN), and Ugt1 and Ugt2 expressions were measured
using SYBR Green quantitative PCR primers and TaqMan quantitative PCR
probe mixes (Life Technologies), respectively. Amplifications were performed
in duplicate on a QuantStudio 6 Flex Real-Time PCR System (Life Technol-
ogies). Data were analyzed using the comparative threshold cycle method as
described by Applied Biosystems (Waltham, MA). Relative expression was
determined by normalizing samples to 18S rRNA expression.
Microsome Preparation. Liver microsomes were prepared from 3 to 5
month old males. Median and left lobes of each liver were harvested after
systemic perfusion with phosphate-buffered saline and homogenized manually
in 0.05 M phosphate buffer (pH 7.4) with 0.154 M potassium chloride and
0.25 M sucrose. Homogenate was centrifuged twice at 10,000g for 10 minutes,
and the postmitochondrial fraction was removed and centrifuged at 100,000g for
45 minutes. Microsomal pellets were washed with homogenization buffer and
resuspended in 0.1 M phosphate buffer (pH 7.4) with 20% glycerol (v/v) and
1 mM EDTA. All preparation steps were performed at 4C. Microsomal protein
concentration was determined using Bio-Rad Protein Assay Dye (Bio-Rad
Laboratories, Hercules, CA) with bovine serum albumin as a standard. Micro-
somes were stored at280C until used and underwent no more than one freeze/
thaw cycle before experimentation.
High-Performance Liquid Chromatography (HPLC). HPLC was per-
formed on an Agilent Technologies 1200 Series instrument. The system is
comprised of a binary solvent pump with temperature-controlled autosampler,
on-line degasser, variable-wavelength UV-visible detector, temperature-
controlled column oven, and automated fraction collector. Chromatographic
protocols are detailed in Table 1. Identities of all glucuronide peaks were verified
by comparison with an authentic standard and by loss of the peak after
b-glucuronidase treatment.
Microsomal Glucuronidation Assays. Glucuronidation reaction mixtures
contained 0.1 M Tris buffer (pH 7.5), 4 mM magnesium chloride, substrate, and
the indicated amount of microsomes in a final volume of 500 ml. Total organic
solvent concentrations were less than 0.7% (v/v). Naproxen glucuronidation
reactions contained 25 mg/ml alamethicin; BPA glucuronidation was performed
both with and without alamethicin. After preincubation on ice and preheating at
37C for 5 minutes, reactions were initiated by addition of UDPGA to a final
concentration of 5 mM and incubated at 37C. Reactions were terminated by
addition to an equal volume of ice-cold 4% acetic acid in methanol (v/v) and
vortex mixing. Microsomal protein was removed by centrifugation at 10,000g
for 10 minutes at 4C, and 30ml of supernatant was analyzed by HPLC. Controls
included baseline measurements and blanks lacking UDPGA. Glucuronide
cleavage was performed by incubation of samples with 1000 units of
b-glucuronidase for 4 hours at pH 5 to 6. Retention times for naproxen and its
glurcuronide, napG, were 8.4 and 4.7 minutes, respectively. Consistent with
previous studies (Bowalgaha et al., 2005), the napG standard was unstable, and
napGwas quantified based on a standard curve for naproxen, which was linear in
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the range of 1–100 mM (r2 . 0.999). The lower limit of detection was 1 mM
for naproxen and napG. Retention times for BPA and BPAG were 15.2 and
12.8 minutes, respectively. Standard curves for BPA and BPAG were linear in
the range of 0.5 mM to 1 mM (r2 . 0.999 for both), and the lower limit of
quantification was 0.5 mM for BPA and BPAG. Kinetics data were analyzed
using Microsoft Excel 2010 and GraphPad Prism version 4.0 software (GraphPad
Software, La Jolla, CA).
In Vivo BPA Glucuronidation. Age- and weight-matched WT and DUgt2
mice were anesthetized with urethane, and the bile duct was cannulated. After
collection of a sample of bile prior to dosage, mice received BPA intravenously
as a bolus in 10% ethanol/water (v/v). Two BPA dosage levels were examined: 2
and 20mgBPA/kg b.wt. Bile fractions were collected in 10minute intervals over
the next 50 minutes. Samples were diluted 1:40 in deionized water, and 30 ml
of each sample were analyzed by HPLC. Retention time for BPAG was
5.7 minutes. Standard curves for BPAG were linear in the range of 0.5 mM to
1mM (r2. 0.999) and the lower limit of quantification was 0.5mM for BPA and
BPAG.
Results
Generation of Mouse Line and Verification of DUgt2 Locus. The
Ugt2 genes are located in a segment of DNA on chromosome 5 between
Ythdc1 and Sult1b1 (Fig. 1). While numerous polymorphisms distin-
guish the Ugt2 locus of the 129 strain from that of C57BL/6, no
difference in the number and overall organization of the genes was
identified by PCR, sequence, or Southern blot analysis. Therefore,
using the organization of the published C57BL/6 locus as a guide, we
generated a targeting vector designed to remove the entire gene family
in a single recombination event in 129 derived ES cells. The deletion
was designed to leave the Ythdc1 and Sult1b1 genes, including
regulatory regions, intact (Fig. 1). Sult1b1 encodes a sulfotransferase
enzyme that contributes to conjugation and excretion of endo- and
xenobiotics, and therefore any compromise in the expression of this
gene would complicate interpretation of the phenotypes of the UGT2-
deficient animals. ES cells were identified where the targeting vector
had integrated into the Ugt2 locus. These were analyzed to ensure that
the recombination event had occurred at the predicted locations in the
mouse genome and had resulted in loss of all Ugt2 genes. This analysis
included extensive PCR, sequence, and Southern blot analyses. ES
cells that met these criteria were used to generate a mouse line. For
simplicity, we refer to this mutation as the DUgt2 allele. The DUgt2
allele was maintained on the 129S6 genetic background by breeding
transmitting chimeras to purchased 129S6 dams.Mice heterozygous for
the deletion were intercrossed to generate mice homozygous for the
allele. DNA from these pups was used to further verify the loss of all
Ugt2 genes by examination of both DNA and RNA from these animals.
A probe was generated by PCR from exon 1 ofUgt2b38 that is expected
to bind to multiple sites throughout the deleted segment, including the
first exons of Ugt2b5, Ugt2b37, Ugt2b36, and Ugt2b35 as well as the
intergenic region betweenUgt2a3 andUgt2b38. Analysis of DNA from
pups generated by intercross of heterozygous parents showed that this
probe failed to bind to DNA from the homozygous DUgt2 offspring
(Fig. 2A). As expected, probes corresponding to regions flanking the
deletion bound to the DNA from these animals and identified the
predicted, novel DNA fragments generated by the recombination event.
RNA was prepared from the nasal epithelium and liver of homozy-
gous DUgt2 animals and their WT littermates. As expected, high levels
ofUgt2a1/2 expression were observed in epithelium fromWT animals,
while expression was absent in samples collected from the null mice
(Fig. 2B). Expression of members of the Ugt2b subfamily and Ugt2a3
were examined in RNA prepared from the liver. Again, expression of
these genes was easily detected in the WT animals, whereas no signal
was observed in DUgt2 animals (Fig. 2C). Taken together, these data
support the DNA analysis indicating that theDUgt2mice lack allUgt2b
and Ugt2a genes.
Development and Reproductive Behavior of the DUgt2 Mouse.
Mice lacking the Ugt2 genes were present in litters at expected
Mendelian ratios. The growth and development of the mice were
normal, and they could not be distinguished by observation from their
WT littermates. The human UGT2B enzymes, including UGT2B4,
UGT2B7, UGT2B15, and UGT2B17, have been shown to participate in
the glucuronidation of endogenous steroids as well as xenobiotics (Hum
et al., 1999). Alteration in steroid metabolism could dramatically alter
the development of primary and secondary sex organs, and thus impair
TABLE 1
Chromatographic protocols
The aqueous solvent (A) was 0.1% acetic acid in water (v/v) and the organic solvent (B) was 0.1% acetic acid in acetonitrile (v/v). The autosampler chamber was held at 6C, and columns were held
at 25C for all experiments. The protocol for BPA in vivo is based on that of Yokota et al. (1999).
Assay Column l Flow Rate Elution Program
nm ml/min
Naproxen in vitro Zorbax Eclipse XDB-C18 (150  4.6 mm, 5mm) 225 1.50 30% B from 0 to 5 minutes
Linear increase to 70% B from 5 to 5.5 minutes
Linear increase to70% B from 5.5 to 10 minutes
BPA in vitro Zorbax Eclipse XDB-C18 (150  4.6 mm, 5mm) 280 0.50 15% B from 0 to 4.5 minutes
Linear increase to 60% B from 4.5 to 5 minutes
Linear increase to 60% B from 5 to 16 minutes
BPA in vivo Tosoh TSKgel ODS 80TM (250  4.6 mm, 5 mm) 280 1.00 Isocratic 35% B
Fig. 1. Schematic drawing showing the structure of the
WT and DUgt2 loci. The locus includes all three Ugt2a
and seven Ugt2b genes and is located between Ythdc1
and Sult1b1 on chromosome 5. The 609 kbp segment of
DNA deleted during the homologous recombination
event is indicated, and the structure of the DUgt2 locus
is shown below. The locus carries marker genes, and
vector sequences are shown in red. The blue arrows
show primers used in the initial screening of ES cell
clones to identify those in which the deletion vector is
inserted by homologous recombination.
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the fecundity of mice. Therefore, we intercrossed mice homozygous for
theDUgt2 locus withWT littermates. The number of pups born to dams
was within the normal size range (Supplemental Fig. 1). Furthermore,
whenDUgt2males were presented with fertile WT females, the interval
until the first mating, the number of matings, the percentage of matings
resulting in pregnancies, and the size of the resulting litters were not
significantly different when compared with WT males (Supplemental
Fig. 2). To further examine this point, male mice were sacrificed at
8 weeks, and their body weight and the sizes of their testes and
seminiferous tubules were examined. No difference in the development
of these organs was observed, consistent with the normal fertility of
these animals (Supplemental Fig. 3). Serum testosterone levels measured
in individually housed, 5 to 6 month old male mice did not differ
significantly from controls (Supplemental Fig. 4).
Gene Expression. The health of the DUgt2 animals could reflect
compensation for the loss of Ugt2 genes by increased expression of
Ugt1s since substantial overlaps in the activities of these two enzyme
families have been documented in both humans and rats (Radominska-
Pandya et al., 1999; Lin and Wong, 2002; Bock, 2010). Increased
expression ofUgt1 isoforms in response to loss of theUgt2 genes would
impact any conclusions drawn regarding observed differences in the
metabolism of chemicals by the DUgt2 animals. As mentioned
previously, the Ugt1 isoforms each have a unique 59 exon. Primers
specific for the first exons of Ugt1a1, Ugt1a7, and Ugt1a9 were
generated and each was paired with a common reverse primer
corresponding to the shared second exon. Quantitative PCR analysis
using these primers revealed that expression patterns for these three
Ugt1 mRNAs are similar to those reported previously (Buckley and
Klaassen, 2007). When compared with WT mice, DUgt2 mice showed
no significant difference in expression of any of the three mRNAs in
the adrenal gland, liver, prostate, epididymis, or testes (Fig. 3). This
indicates that the normal development of these mice does not reflect
compensation for loss of these genes by increased expression of UGT1
isoforms. These results also support the general usefulness of this
mouse line for determining the contribution of the Ugt2 genes to
xenobiotic metabolism.
Naproxen Glucuronidation. To demonstrate the usefulness of the
DUgt2 mice in evaluation of the role of UGT2 enzymes in xenobiotic
metabolism, we examined the ability of liver microsomes from these
mice to metabolize naproxen. We chose this assay because a number of
lines of evidence indicate that human and rat UGT2 isoforms show
selectivity toward this substrate (el Mouelhi et al., 1987; Pritchard et al.,
1994; Bowalgaha et al., 2005; Sanoh et al., 2012). Microsomes from
DUgt2 and co-isogenic WT controls were incubated with naproxen for
2 hours, and supernatant was analyzed by HPLC for the presence of the
glucuronide. Microsomes from WT mice formed 46.2 6 1.9 (mean 6
S.E.M., n = 3) nmol of napG per mg microsomal protein, while
microsomes from DUgt2 mice showed no detectable amount of
glucuronide formation (Fig. 4). These data indicate loss of activity
against UGT2-specific substrates in the DUgt2 animals and support the
utility of this mouse line in assigning glucuronidation of xenobiotics to
the Ugt2 gene family.
BPA Glucuronidation. We next asked whether DUgt2 mice could
be used to measure the contribution of UGT2 enzymes to the
metabolism of xenobiotics metabolized by both UGT families. Studies
Fig. 2. Verification of the deletion of Ugt2 genes. (A) DNA was
prepared from tail biopsies of homozygous WT, homozygous
DUgt2, and heterozygous pups, digested with BamHI, and
analyzed by Southern blot. A probe corresponding to a region just
outside the Ugt2 locus was used to verify the genotypes of the
mice and the integrity of the DNA. As predicted, it hybridized to
11 and 6.45 kbp DNA fragments corresponding to the WT allele
and DUgt2 locus, respectively (upper panel). The filter was then
analyzed with a probe binding to BamHI fragments corresponding
to a conserved region in Ugt2a3, Ugt2b1, Ugt2b5, and Ugt2b35
(lower panel). The WT locus yielded four different fragments
(15.38, 15.23, 10, and 9.57 kbp), as expected. Consistent with the
excision of the entire Ugt2 locus during a single recombination
event, no hybridization of the probe is observed in the lanes
corresponding to the mice homozygous for the DUgt2 locus. (B)
RNA from olfactory epithelium was analyzed by quantitative PCR
for Ugt2a1/2, normalized to 18S expression. As expected, robust
expression is observed in WT mice, while none was detected in
the DUgt2 animals, as indicated by the asterisks. The quality and
epithelial origin of the RNA was verified by showing that Cftr
expression was robust and that the expression level did not differ
between the DUgt2 and WT animals. (C) RNA prepared from
liver was analyzed by quantitative PCR for expression of Ugt2b1,
Ugt2b35, Ugt2b5, and Ugt2a3 and normalized to 18S expression.
N = 3 for all samples and error bars represent the S.E.M.
Fig. 3. Expression and tissue distribution of Ugt1a mRNAs in WT and DUgt2 mice.
Ugt1a expression levels were measured by quantitative real-time PCR with a SYBR
Green quantitative PCR Master Mix. Primers were designed to amplify across the
junction between the unique first exon for each isoform and the shared exons. cDNA
samples were diluted to 10 pg/ml for amplification with the 18S probe and to
2.5 ng/ml for all other probes. The comparative threshold cycle method was used
to quantify the relative gene expression. The amount of target was normalized to
18S as an endogenous reference and to WT adrenal gland as a calibrator.
Expression of the examined isoforms did not differ significantly in any tissue
examined between WT and DUgt2 animals. Amplifications were performed in
duplicate. Error bars represent the S.E.M. (n = 3).
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using recombinant human and rat UGTs have shown that BPA is
a substrate for both enzyme families, with greater activity assigned to
UGT2 enzymes (Yokota et al., 1999; Hanioka et al., 2008, 2011).
Therefore, we first determined whether UGT2 enzymes are exclusively
responsible for the metabolism of BPA by mouse microsomes. Micro-
somes prepared from pairs of WT and DUgt mice were incubated with
BPA and the cofactor UDPGA for 2 hours. The quantities of BPA and
BPAG in the reaction products were determined by HPLC. Under these
conditions, rapid and complete metabolism of BPA was observed in
reactions carried out using both WT and mutant microsomes. No
difference was observed between DUgt2 and WT microsomes in the
total amount of BPAG produced (Fig. 5D). Thus, glucuronidation of
BPA occurs in the absence of all UGT2 enzymes. Presumably, this
conjugation is carried out by UGT1 enzymes. However, because the
reactions were allowed to go to completion these experiments could not
differentiate between the contributions of UGT1s and UGT2s to BPA
glucuronidation.
By examining the kinetics of BPA glucuronidation inWT andDUgt2
microsomes, the activities of the two enzyme families can be examined.
The activity of WT microsomes is expected to represent the sum of the
activities of the UGT1 and UGT2 families, whereas the activity of
DUgt2 microsomes represents that of the UGT1 family alone.
Reaction conditions were optimized to allow measurement of differ-
ences in activity betweenWT and DUgt2microsomes by increasing the
substrate-to-enzyme ratio and by removal of alamethicin. Alamethicin
increases the rate of glucuronidation in microsomes by facilitating the
movement of the substrate and UDPGA through the microsomal lipid
bilayer. Thus, removal of alamethicin from the glucuronidation
reactions decreased the reaction rates and facilitated kinetic analysis of
the rapidly metabolized substrate. As shown in Fig. 5, under these
conditions, the ability of UGT2 enzymes to contribute to BPA
metabolism is easily observed. BPA glucuronidation exhibited
Michaelis-Menten kinetics in bothWT and DUgt2microsomes. Curves
were fit to plots of glucuronidation rate (pmol/min/mg microsomal
protein) versus BPA concentration (Fig. 5E). The kinetic parameters are
given in Table 2. The Vmax measured for DUgt2 microsomes, which
contain only UGT1 enzymes, is approximately 50% lower than that
of WT microsomes, which contain UGT1s and UGT2s. This 50%
decrease is attributed to the absence of the UGT2 enzymes in DUgt2
microsomes. Thus, we concluded that 50% of the activity in WT
microsomes was due to UGT2s and 50% to UGT1s, suggesting the
activities of the two families are approximately equal. The Km value did
not differ significantly between the WT and the DUgt2 microsomes.
This suggests that, under these conditions, the two murine UGT
families have approximately equal activity toward, and affinity for,
BPA. To ensure that the exclusion of alamethicin did not alter the
relative activities of microsomes derived from the two mouse lines, WT
and DUgt2microsomes were incubated with 100 mMBPA either in the
presence or absence of alamethicin. Significant differences between
WT and DUgt2 microsomes are present under both alamethicin-
activated and nonactivated conditions, and the ratio of WT activity to
DUgt2 activity is comparable in both cases (Supplemental Fig. 5). This
result is consistent with previous studies (Fisher et al., 2000) suggesting
that alamethicin has an isoform-independent activating effect on UGTs.
To further evaluate the relative contributions of the twoUGT families
to microsomal BPA glucuronidation, we used our data sets to derive
theoretical kinetic parameters for the UGT1 and UGT2 enzymes,
assuming that all BPAG detected was formed by these two enzyme
families. Since DUgt2 mice express only UGT1 enzymes, the kinetic
parameters of the DUgt2microsomes are assigned to the UGT1 family.
Fig. 4. Naproxen glucuronidation by liver microsomes from
WT andDUgt2mice. Reactions contained 50–150mg microsomal
protein, 25 mg/ml alamethicin, 100 mM naproxen, and 5 mM
UDPGA. (A) Typical chromatogram of reaction products of WT
microsomes. (B) Typical chromatogram of reaction products of
DUgt2 microsomes. (C) Typical chromatogram of a control
reaction lacking UDPGA. Microsomes from WT mice formed
46.2 6 1.9 (mean 6 S.E.M., n = 3) nmol NapG/mg of protein,
while microsomes from DUgt2 mice showed no detectable
amount of glucuronide formation.
Fig. 5. BPA glucuronidation by liver microsomes from WT and
DUgt2mice. (A) Typical chromatogram of products of a reaction
terminated immediately after addition of UDPGA. (B) Typical
chromatogram of products of a reaction terminated after 10 minutes
of incubation. (C) The identity of the BPAG peak was verified by
its loss after treatment with b-glucuronidase. (D) BPAG formation
after 2-hour incubation of BPA and 25 mg/ml alamethicin with WT
and DUgt2 microsomes. Complete substrate conversion was
observed, and BPAG concentrations were not significantly
different. (E) Michaelis-Menten curves for glucuronidation of
BPA by microsomes prepared from WT (squares) and DUgt2
(triangles) mice in the absence of alamethicin. Each data point
represents microsomal preparations from four mice. Error bars
represent S.D. r2 . 0.95 for WT mice and r2 . 0.85 for DUgt2
mice. Reactions contained 20–60 mg microsomal protein, 5–100 mM
BPA, and 5 mM UDPGA.
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Glucuronidation of BPA in WT microsomes was assumed to represent
the sum of the activities of both UGT2 and UGT1 enzymes, and
theoretical Km and Vmax values for the UGT2 family were derived using
the two-enzyme Michaelis-Menten equation (Segel, 1993):
VWT ¼ ðVmaxUGT1Þ½SKmUGT1 þ ½S
þ ðVmaxUGT2Þ½S
KmUGT2 þ ½S
where V is the rate of reaction; [S] is the concentration of the substrate;
and Km and Vmax are the Michaelis constant for and maximum rate
attributed to each UGT family, respectively. As shown subsequently,
UGT2 activity can be represented by the difference in the glucuroni-
dation rate between WT mice and DUgt2 counterparts:
ðVmaxUGT2Þ½S
KmUGT2 þ ½S
¼ VWT 2 ðVmaxUGT1Þ½SKmUGT1 þ ½S
¼ VWT 2VDUgt2
Thus, UGT2-mediated BPA glucuronidation was modeled using
a Michaelis-Menten curve fitted to a plot of the difference in rate
between paired WT and DUgt2 microsomes at each substrate concen-
tration (Fig. 6). The kinetic parameters are given in Table 3. Based on
this analysis, the activities and affinities of the UGT1 and UGT2
enzymes toward BPA are predicted to be very similar.
BPA Metabolism In Vivo. Evaluation of BPA glucuronidation by
DUgt2 and WT microsomes indicates that UGT1 and UGT2 enzymes
contribute equally to BPA metabolism. To determine whether this
predicts the activities of these gene families in vivo, we examined the
metabolism of BPA inWT and mutant animals. The bile ducts of paired
WT andDUgt2male mice matched for weight and age were cannulated.
After collection of a predose bile sample for use as a baseline control,
each animal received a single bolus of BPA delivered intravenously.
Fractions of bile were collected over the next 50 minutes, and the
quantity of BPAG in each bile fraction was determined by HLPC. No
significant difference was seen in the volume or rate of bile production
by theDUgt2 andWT animals, and BPAG accumulation in the bile was
linear over the 50 minute collection in both mouse lines. The biliary
excretion rate was therefore expressed as the fraction of the initial BPA
dose excreted per minute.
As expected, based on the study of DUgt2 microsomes, BPAG was
detected in the bile of the DUgt2mice, clearly indicating that the UGT1
family glucuronidates BPA in vivo.More surprisingly, following a dose
of 2 mg BPA/kg b.wt., no significant difference between the rate of
biliary BPA excretion in WT and DUgt2 mice was observed (Fig. 7).
This result suggests that the impact of the UGT2 family on BPA
clearance is minimal at this exposure level and that the UGT1 family
has significant capacity for BPA conjugation in vivo. When the BPA
dose was increased to 20 mg/kg b.wt., a significant decrease between
the average biliary excretion rates for WT and DUgt2 mice was
observed. Approximately 0.31% of the BPA dose was glucuronidated
and excreted per minute by WT mice. However, in mutants only 0.22%
of the initial dose was glucuronidated and excreted per minute,
approximately a 28% reduction in excretion rate (Fig. 7). A significant
contribution of the UGT2s to BPA clearance was only observable at this
extremely high dose of BPA. Male mice were used in these studies to
avoid potential increases in animal-to-animal variation due to the
estrous cycle in females; however, examination of hepatic BPA
glucuronidation after a dosage of 2 mg BPA/kg b.wt. in female mice
also failed to reveal a significant difference between WT and DUgt2
animals (Supplemental Fig. 6). Thus, we conclude that the UGT1
family is primarily responsible for the rapid glucuronidation and
clearance of BPA in male and female mice.
Discussion
In this study, we show the generation of mice lacking the ;600 kbp
DNA segment carrying the Ugt2 gene family. Unlike mice lacking the
UGT1 enzymes (Nguyen et al., 2008), the mice are healthy and
indistinguishable from control animals when bred in a specific
pathogen–free animal facility. While the UGT1 family is essential for
the conjugation and excretion of endogenous metabolites, our data
indicate that the members of the UGT2 family do not play an essential
and unique role in this function. Particularly surprising is the fact that
the loss of UGT2 enzymes does not significantly alter sexual develop-
ment or fertility, given the ability of both rodent and human UGT2s to
metabolize steroid hormones, particularly androgens (Hum et al., 1999;
Chouinard et al., 2008). Studies using mice lacking the androgen
receptor or mice treated with antiandrogens such as cyproterone acetate
have shown that the development of the secondary sex organs is
sensitive to androgen levels (Jean-Faucher et al., 1984; Yeh et al.,
2002). Both of these studies reported impaired development of
secondary sex organs observable at a gross anatomic level as well as
infertility when androgen metabolism was impaired. This indicates that
the normal development of these organs is a sensitive surrogate marker
for normal androgenmetabolism in mice. A possible explanation for the
lack of a developmental or reproductive phenotype in the mutants is that
glucuronidation is not a critical pathway for androgen excretion in mice.
There is evidence that sulfonation is the predominant excretory
pathway for some substrates in rodents (Sanoh et al., 2012), and
a number of steroid-conjugating sulfotransferases, including the
estrogen-preferring SULT1E1 and the hydroxysteroid sulfotransferases
TABLE 2
Kinetic parameters for BPA glucuronidation in liver microsomes from WT and
DUgt2 mice
Values are expressed as the mean 6 S.D. (n = 4). Vmax is significantly different at the P ,
0.0001 level and Km is not significantly different in unpaired Student’s t tests.
Vmax Km
pmol/min/mg mM
WT 1220.0 6 61.4 9.17 6 1.73
DUgt2 553.2 6 35.2 7.16 6 1.87
Fig. 6. Enzyme kinetics of UGT1- and UGT2-mediated BPA glucuronidation. The
glucuronidation activity remaining in mutant mice after deletion of the Ugt2s was
assigned to the UGT1 family (circles). The difference in glucuronidation rate
measured between microsomes from WT and DUgt2 animals was used to represent
activity of the UGT2 family (triangles). The calculated kinetics of glucuronidation of
BPA by both enzyme families was consistent with the Michaelis-Menten models.
Calculations assumed equal concentrations of UGT1 and UGT2 enzymes in WT
microsomes. r2 . 0.85 for UGT1s and r2 . 0.75 for UGT2s. Error bars represent
the S.E.M., n = 4 microsomal preparations of each genotype.
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SULT2A1 and SULT2B1, could contribute to androgen metabolism
(Alnouti and Klaassen, 2006). Supporting this possibility, neither the
Gunn rat (Nguyen et al., 2008) nor the DUgt2 mouse exhibits altered
fertility or sexual development, while the Sult1e1 knockout mouse
exhibits alterations in both capacities (Qian et al., 2001).
TheUgt2a genes are located in the same cluster as theUgt2b genes in
both humans and rodents.Ugt2a1 andUgt2a2 are expressed in the nasal
epithelium, and studies using recombinant enzymes have shown that
they are able to conjugate odorants. This is hypothesized to be
important in the termination of odorant signaling and preventing
receptor desensitization (Lazard et al., 1991; Sneitz et al., 2009). The
DUgt2 mouse line should allow this hypothesis to be tested, both in
vitro using cultured nasal epithelial cells and in vivo using odor-
dependent behavioral paradigms (Friedrich, 2006). While the function
of Ugt2a3 remains unclear (Buckley and Klaassen, 2009; Sneitz et al.,
2009), its conservation across species suggests a role in excretion of
endogenous metabolites (Mackenzie et al., 2005). However, our studies
indicate that, at least in mice bred in a vivarium, this gene is not essential
for normal development and health.
Previous studies using recombinant UGT2 enzymes indicate that the
UGT2 family is important in the metabolism of many nonsteroidal anti-
inflammatory drugs in both humans and rats (King et al., 2000). Using
microsomes prepared from the DUgt2 mice, we show that glucuroni-
dation of naproxen is dependent on the UGT2 enzymes. Even after
extended incubation, only the parent compound was detected in DUgt2
microsomal reaction products. However, we cannot exclude the
possibility that some glucuronidation may be detected at higher
substrate concentrations due to low-affinity interaction with UGT1
isoforms. Such interactions have been observed using recombinant
human UGT1s (Bowalgaha et al., 2005). Studies using recombinant rat
UGT enzymes indicate that UGT2B1 shows high activity toward many
nonsteroidal anti-inflammatory drugs, including naproxen (Ritter,
2000). While our studies only allow assignment to the UGT2 enzyme
family and not individual isoforms, it is likely that naproxen metabo-
lism in the mouse is dependent on Ugt2b1 expression.
Extensive studies have confirmed widespread human exposure to
BPA (Vandenberg et al., 2007), and studies carried out in both rats and
mice indicate possible adverse effects of BPA on development and
health (Kabuto et al., 2004; Richter et al., 2007; Vandenberg et al.,
2007; Hanioka et al., 2008). Considerable resources have been directed
toward determination of the health risks associated with BPA
exposure. Despite the interest in this xenobiotic, the understanding of
its metabolism is incomplete. BPA is rapidly glucuronidated in both
humans and rodents and excreted through urine and bile, respectively.
However, less is known regarding the enzymes primarily responsible
for formation of the glucuronide. Assigning this activity to the
individual enzymes of the UGT1 and UGT2 families has relied largely
on studies using recombinant enzymes. Studies of both human and rat
enzymes indicate that the UGT2s, specifically UGT2B15 in human
and UGT2B1 in rat, show the highest activity toward BPA. Therefore,
it has been assumed that the UGT2 family is critical for rapid clearance
of this xenobiotic. Our results are not consistent with this model and
indicate that UGT1 enzymes generate a larger proportion of BPAG
in vivo. One possibility is that Ugt1a9, orthologous to the BPA-
conjugating human UGT1A9 (Hanioka et al., 2008), is a pseudogene in
rats but functional in mice (Mackenzie et al., 2005). Thus, the UGT1s
may make a larger relative contribution to BPA glucuronidation in
mice than in rats.
The role of the UGT1s in BPA metabolism became apparent upon
incubation of BPA with microsomes isolated from DUgt2 mice. When
allowed to go to completion, reactions containing WT and DUgt2
microsomes with equal initial concentrations of BPA formed equal
concentrations of BPAG. A contribution of UGT2s to BPA metabolism
could be defined by examining the rate of formation of the glucuronide,
and a 50% reduction was observed in the Vmax of DUgt2 microsomes
when compared with WT controls. The approximately equal contribu-
tions of UGT1s and UGT2s to BPAmetabolism in these in vitro studies
did not accurately predict the impact of UGT2 deficiency on BPA
TABLE 3
Kinetic parameters for BPA glucuronidation by mouse UGT1s and UGT2s
Values are expressed as the mean 6 S.E.M. (n = 4). Neither Vmax nor Km is significantly
different in an unpaired Student’s t test.
Vmax Km
pmol/min/mg mM
UGT2 665.5 6 73.1 10.99 6 4.27
UGT1 553.2 6 35.2 7.16 6 1.87
Fig. 7. In vivo BPA glucuronidation in WT and DUgt2 mice.
(A) Typical chromatogram of bile collected from a DUgt2 mouse
prior to dosage. (B) Typical chromatogram of a bile fraction
collected from a DUgt2 mouse from 0 to 10 minutes after
dosage. (C) Treatment with b-glucuronidase causes loss of the
BPAG peak and changes in the chromatographic profile due to
deconjugation of endogenous glucuronides. BPAG peak areas
were corrected for the area of a small interfering peak
(presumably due to a co-eluting endogenous metabolite; marked
by an asterisk) in bile obtained immediately before dosage. The
interfering peak remained after b-glucuronidase treatment,
indicating that it does not represent BPA exposure prior to
experimentation. (D) Average BPAG excretion after dosage
with 2 mg/kg BPA over the collection period for WT and
DUgt2 male mice, measured as percentage of dose/minute.
Average excretion rates for WT and DUgt2 mice were 0.306 6
0.030 (mean 6 S.E.M., n = 3) and 0.325 6 0.039 (mean 6
S.E.M., n = 3) respectively. (E) Average BPAG excretion after
dosage with 20 mg/kg BPA over the collection period for WT
and DUgt2 mice. Average excretion rates for WT and DUgt2
mice were 0.313 6 0.019 (mean 6 S.E.M., n = 6) and 0.224 6
0.024 (mean 6 S.E.M., n = 7) respectively. Average percent
excretion/minute was significantly different at the P , 0.05
level in an unpaired Student’s t test. BPAG excretion was
linear over the time range examined (plots of percent excretion
versus time had r2 . 0.93 for all animals).
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metabolism in vivo. At a dose of 2 mg/kg, orders of magnitude greater
than the estimated 1.5mg/kg exposure for the general human population
(European Union, 2010), there was no significant difference in biliary
BPA excretion between WT and DUgt2 mice. Only when the dosage
was increased to 20 mg/kg was a significant difference observed.
These data indicate that the UGT1 family has extensive capacity to
glucuronidate BPA and that this enzyme family may, in fact, be
primarily responsible for BPA metabolism in vivo. Barring extreme
exposures, the contribution of UGT2s to hepatic conjugation of BPA
may be negligible.
This work highlights the limitations of directly extrapolating the
results of in vitro studies to in vivo metabolism of xenobiotics, which
have been extensively discussed previously (Lin and Wong, 2002;
Soars et al., 2002; Miners et al., 2006). In general, in vitro studies are
reported to underestimate in vivo enzymatic activities. In the case of
the DUgt2 mice, the in vitro results underestimated the contribution
of the UGT1 family to BPA metabolism. One possible explanation
could be the differential stability of mouse UGT2s and UGT1s during
microsomal preparation or incubation, as has been observed in the
glucuronidation of flavonoids (Joseph et al., 2007), thereby exagger-
ating the contribution of one family over the other in in vitro studies. It
is also possible that differential localization of UGT1 and UGT2
enzymes in the liver results in differential access to BPA in an in vivo
environment. Additional experiments, including evaluation of BPA
metabolism by primary mouse hepatocytes, could help to distinguish
between these possibilities.
Several human UGT isoforms are capable of conjugating BPA.
UGT2B15 is reported to have the highest activity, with lower activities
observed for recombinant UGT1A1, UGT1A3, UGT1A9, UGT2B4,
and UGT2B7 (Hanioka et al., 2008). An important issue impacted by
the assignment of BPA primarily to the UGT2 family is the ability of
neonates to metabolize BPA. Neonates and infants have reduced levels
of UGT2 expression until 6 to 7 months of age. Therefore, they may
represent a subpopulation with increased susceptibility to BPA’s
adverse effects (Strassburg et al., 2002; Zaya et al., 2006; Divakaran
et al., 2014). Concern regarding the ability of the newborn to metabolize
BPA is the basis for restricting the use of BPA-containing plastics in
infant bottles in some countries. However, if human UGT1 enzymes
contribute extensively to BPA metabolism, as we have found to be the
case in mice, this concern may not be well-founded. UGT1A9 reaches
adult levels by 4 months, and expression of UGT1A1 increases rapidly
after birth due to the necessity of bilirubin conjugation, which occurs in
the maternal liver via transfer across the placenta prior to birth
(Schenker et al., 1964; Onishi et al., 1979; Miyagi et al., 2012). While
we cannot rule out the possibility that the predominant role of UGT1s in
BPA metabolism is unique to the mouse, the UGT1 family is more
closely conserved between species than the UGT2 family, suggesting
that members of the UGT1 family may play a major role in BPA
glucuronidation in humans.
In summary, we describe here the generation of a mouse line
allowing definitive assignment of metabolism of xenobiotics to the
UGT1 or UGT2 enzyme family. The normal development and good
health of these animals makes them an ideal model for such studies.
Reconstitution of the deleted locus with individual mouse or human
UGT2 genes will provide a means of refining functional assignments to
individual UGT2 enzymes in vivo.
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